Lin Qiao, Cao Yunpeng, Gao Jie
Department of Internal Medicine, the Fourth Affiliated Hospital of China Medical University, Shenyang 110005, China.
Neural Department of Internal Medicine, the First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Int J Mol Sci. 2014 Nov 25;15(12):21740-53. doi: 10.3390/ijms151221740.
Calreticulin is down-regulated in the cortical neurons of patients with Alzheimer's disease (AD) and may be a potential biomarker for the diagnosis of AD. A total of 128 AD patients were randomly recruited from May 2012 to July 2013. The mRNA levels of calreticulin were measured from the serum of tested subjects using real-time quantitative reverse transcriptase-PCR (real-time qRT-PCR). Serum levels of calreticulin were determined by ELISA and Western Blot. Serum levels of calreticulin in AD patients were significantly lower than those from a healthy group (p < 0.01). The baseline characters indicated that sample size, gender, mean age, diabetes and BMI (body mass index) were not major sources of heterogeneity. The serum levels of mRNA and protein of calreticulin were lower in AD patients than those from a healthy group, and negatively associated with the progression of AD according to CDR scores (p < 0.01). Thus, there is a trend toward decreased serum levels of calreticulin in the patients with progression of AD. Serum levels of calreticulin can be a negative biomarker for the diagnosis of AD patients.
钙网蛋白在阿尔茨海默病（AD）患者的皮质神经元中表达下调，可能是诊断AD的潜在生物标志物。2012年5月至2013年7月期间，共随机招募了128例AD患者。使用实时定量逆转录聚合酶链反应（实时qRT-PCR）从受试对象的血清中测量钙网蛋白的mRNA水平。通过酶联免疫吸附测定（ELISA）和蛋白质印迹法（Western Blot）测定血清钙网蛋白水平。AD患者的血清钙网蛋白水平显著低于健康组（p < 0.01）。基线特征表明，样本量、性别、平均年龄、糖尿病和体重指数（BMI）不是异质性的主要来源。AD患者血清中钙网蛋白的mRNA和蛋白质水平低于健康组，并且根据临床痴呆评定量表（CDR）评分与AD的进展呈负相关（p < 0.01）。因此，随着AD病情进展，患者血清钙网蛋白水平有下降趋势。血清钙网蛋白水平可作为诊断AD患者的阴性生物标志物。
